New 'Bispecific' antibody takes aim at Hard-to-Treat blood cancers
NCT ID NCT02290951
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a drug called odronextamab in 200 people with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia that had stopped responding to prior treatments. The drug is a bispecific antibody designed to bring immune cells close to cancer cells to kill them. The main goals were to check safety and find the right dose, while also looking at whether tumors shrank.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Odronextamab (a bispecific antibody that targets both CD20 on cancer cells and CD3 on immune cells)
What this could lead to
If successful, this could lead to a new treatment option for patients with B-cell cancers who have run out of standard therapies.
What could go wrong
This is an early Phase 1 trial focused on safety, so it is not yet proven to work. Side effects may occur, and the drug may not shrink tumors in most patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Assuta Ashdod University Hospital
Ashdod, Southern District, 7747629, Israel
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
CHU Hôpital Lyon Sud
Lyon, 69495, France
-
Centre Henri Becquerel
Rouen, Haute-Normandie, 76038, France
-
Dana Farber Cancer Institute (Massachusetts General Hospital and Beth Israel)
Boston, Massachusetts, 02215, United States
-
H. Lee Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Hadassah Medical Center
Jerusalem, Jerusalem, 9112001, Israel
-
Institut Gustave Roussy
Villejuif, Île-de-France Region, 94800, France
-
Lady Davis Carmel Medical Center
Haifa, 3436212, Israel
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Meir Medical Center
Kfar Saba, Central District, 44281, Israel
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Rambam Health Care Campus - Hematology and Bone Marrow Transplantation Institute
Haifa, 3109601, Israel
-
Royal Cornwall Hospitals NHS Trust
Truro, Cornwall, tr1 3lq, United Kingdom
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08901, United States
-
Stanford University
Stanford, California, 94305, United States
-
The Chaim Sheba Medical Center
Tel-Hashomer, Central District, 5265601, Israel
-
The Christie NHS Foundation Trust
Manchester, M20 4BX, United Kingdom
-
Universitatsklinikum Wurzburg
Würzburg, Bavaria, 97080, Germany
-
University of California, Irvine
Orange, California, 92868, United States
-
Weill Cornell Medical College
New York, New York, 10065, United States